Research and Markets (http://www.researchandmarkets.com/research/fkgxr3/metastatic) has announced the addition of the "Metastatic Biliary Tract Cancer - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Biliary Tract Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AstraZeneca PLC
- GlaxoSmithKline plc
- Novartis AG
- OncoTherapy Science, Inc.
Drug Profiles
- (dabrafenib mesylate + trametinib dimethyl sulfoxide)
- binimetinib
- OCV-C01
- selumetinib sulfate
- trametinib dimethyl sulfoxide
For more information visit http://www.researchandmarkets.com/research/fkgxr3/metastatic
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.